Livia Alvarenga1, Roberta Salarolli2, Ludmila F M F Cardozo3, Rhayssa S Santos4, Jessyca S de Brito5, Julie Ann Kemp3, Drielly Reis5, Bruna Regis de Paiva3, Peter Stenvinkel6, Bengt Lindholm6, Denis Fouque7, Denise Mafra8. 1. Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Brazil. Electronic address: liviaalvarenga92@gmail.com. 2. Graduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói, Brazil. 3. Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, Brazil. 4. College of Nutrition, Fluminense Federal University (UFF), Niterói, Brazil. 5. Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Brazil. 6. Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Technology and Intervention, Karolinska Institutet, Stockholm, Sweden. 7. Department of Nephrology, Centre Hopitalier Lyon Sud, INSERM 1060, CENS, Université de Lyon, France. 8. Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Brazil; Graduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói, Brazil; Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, Brazil; College of Nutrition, Fluminense Federal University (UFF), Niterói, Brazil.
Abstract
BACKGROUND & AIMS: Chronic kidney disease (CKD) patients have numerous complications associated with inflammation, which is a potential driver for cardiovascular disease. Curcumin, a compound of the curcuminoid class produced by the Curcuma longa, has been reported to activate nuclear factor erythroid factor 2-related (Nrf2) and inhibit nuclear factor kappa-B (NF-kB). Our aim was to evaluate the effects of curcumin juice on the expression of inflammatory transcription factors in hemodialysis (HD) patients. METHODS AND RESULTS: This double-blind randomized pilot study included 31 HD patients divided into two groups: curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months) and control group (receiving the same juice without curcumin); 14 patients in each arm completed the study. The mRNA expression of Nrf2, NF-kB, NLRP3 inflammasome and IL-1β in peripheral blood mononuclear cells (PBMC; using real-time quantitative polymerase chain reaction, qPCR) and routine biochemistries, food intake and anthropometrics were analyzed. After three months of supplementation, the curcumin group showed a significant decrease in NF-kB mRNA expression (AU) [from 1.08 (0.77-1.38) to 0.52 (0.32-0.95),p = 0.02] and in plasma high sensitivity C-reactive protein (hsCRP) levels [from 3.8 (2.5-6.8) to 2.0 (1.1-3.8) mg/L, p = 0.04]. There was no change in the other evaluated markers. CONCLUSION: Three months treatment with curcumin in CKD patients undergoing HD resulted in decreased markers of inflammation, NF-kB mRNA expression and hsCRP, suggesting that oral supplementation of curcumin may have an anti-inflammatory effect in this patient group. TRIAL REGISTRATION: Approved by the Ethics Committee of the Faculty of Medicine/UFF, number: 2.346.933. This study was registered within ClinicalTrials.gov under the number NCT03475017.
BACKGROUND & AIMS: Chronic kidney disease (CKD) patients have numerous complications associated with inflammation, which is a potential driver for cardiovascular disease. Curcumin, a compound of the curcuminoid class produced by the Curcuma longa, has been reported to activate nuclear factor erythroid factor 2-related (Nrf2) and inhibit nuclear factor kappa-B (NF-kB). Our aim was to evaluate the effects of curcumin juice on the expression of inflammatory transcription factors in hemodialysis (HD) patients. METHODS AND RESULTS: This double-blind randomized pilot study included 31 HD patients divided into two groups: curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months) and control group (receiving the same juice without curcumin); 14 patients in each arm completed the study. The mRNA expression of Nrf2, NF-kB, NLRP3 inflammasome and IL-1β in peripheral blood mononuclear cells (PBMC; using real-time quantitative polymerase chain reaction, qPCR) and routine biochemistries, food intake and anthropometrics were analyzed. After three months of supplementation, the curcumin group showed a significant decrease in NF-kB mRNA expression (AU) [from 1.08 (0.77-1.38) to 0.52 (0.32-0.95),p = 0.02] and in plasma high sensitivity C-reactive protein (hsCRP) levels [from 3.8 (2.5-6.8) to 2.0 (1.1-3.8) mg/L, p = 0.04]. There was no change in the other evaluated markers. CONCLUSION: Three months treatment with curcumin in CKD patients undergoing HD resulted in decreased markers of inflammation, NF-kB mRNA expression and hsCRP, suggesting that oral supplementation of curcumin may have an anti-inflammatory effect in this patient group. TRIAL REGISTRATION: Approved by the Ethics Committee of the Faculty of Medicine/UFF, number: 2.346.933. This study was registered within ClinicalTrials.gov under the number NCT03475017.
Authors: Livia Alvarenga; Ludmila F M F Cardozo; Beatriz O Da Cruz; Bruna R Paiva; Denis Fouque; Denise Mafra Journal: Int Urol Nephrol Date: 2022-03-26 Impact factor: 2.266
Authors: Denise Mafra; Ludmila F M F Cardozo; Cristiane Moraes; Lais S G Moreira; Karla T R Teixeira; Drielly C M V Reis; Susane Fanton; Roberta Salarolli; Kamyar Kalantar-Zadeh; Jerrilynn D Burrowe Journal: J Ren Nutr Date: 2020-08-18 Impact factor: 3.655